Page 46 - Read Online

Page 20 of 20 Nwaiwu et al. Mini-invasive Surg. 2025;9:20 https://dx.doi.org/10.20517/2574-1225.2024.112

systematic review and meta-analysis of randomized controlled trials. Obes Surg. 2020;30:2743-53. DOI PubMed
54. Popov VB, Ou A, Schulman AR, Thompson CC. The impact of intragastric balloons on obesity-related co-morbidities: a systematic
review and meta-analysis. Am J Gastroenterol. 2017;112:429-39. DOI PubMed
55. Shah R, Davitkov P, Abu Dayyeh BK, Saumoy M, Murad MH. AGA technical review on intragastric balloons in the management of
obesity. Gastroenterology. 2021;160:1811-30. DOI PubMed
56. FDA. FDA In Brief: postmarket update on liquid-filled intragastric balloons. 2020. Available from: https://www.fda.gov/news-events/
fda-brief/fda-brief-postmarket-update-liquid-filled-intragastric-balloons. [Last accessed on 20 Jun 2025].
57. FDA. Summary of safety and effectiveness data (SSED). TransPyloric Shuttle/TransPyloric Shuttle delivery device. 2019. Available
from: http://www.accessdata.fda.gov/cdrh_docs/pdf10/P100034b.pdf. [Last accessed on 20 Jun 2025].
58. Rothstein RI, Kopjar B, Woodman GE, et al. Randomized double-blind sham-controlled trial of a novel silicone-filled endoscopically
placed device for weight loss. Tech Innov Gastrointest Endosc. 2024;26:21-9. DOI
59. Orlandini B, Gallo C, Boškoski I, Bove V, Costamagna G. Procedures and devices for bariatric and metabolic endoscopy. Ther Adv
Gastrointest Endosc. 2020;13:2631774520925647. DOI PubMed PMC
60. Sauer N, Rösch T, Pezold J, et al. A new endoscopically implantable device (satisphere) for treatment of obesity - efficacy, safety, and
metabolic effects on glucose, insulin, and GLP-1 Levels. Obes Surg. 2013;23:1727-33. DOI PubMed
61. Günthert SJ, Aksan A, Schröder O, et al. Glycemic control and BMI changes after endoscopic implantation of a duodenojejunal bypass
liner compared with laparoscopic Roux-en-Y gastric bypass surgery: a propensity score matching analysis. Surg Endosc.
2022;36:5979-85. DOI PubMed
62. Igi WF, de Oliveira VL, Matar A, de Moura DTH. Role of endoscopic duodenojejunal bypass liner in obesity management and
glycemic control. Clin Endosc. 2024;57:309-16. DOI PubMed PMC
63. Yvamoto EY, de Moura DTH, Proença IM, et al. The effectiveness and safety of the duodenal-jejunal bypass liner (DJBL) for the
management of obesity and glycaemic control: a systematic review and meta-analysis of randomized controlled trials. Obes Surg.
2023;33:585-99. DOI PubMed
64. Sandler BJ, Rumbaut R, Swain CP, et al. One-year human experience with a novel endoluminal, endoscopic gastric bypass sleeve for
morbid obesity. Surg Endosc. 2015;29:3298-303. DOI PubMed
65. Machytka E, Bužga M, Zonca P, et al. Partial jejunal diversion using an incisionless magnetic anastomosis system: 1-year interim
results in patients with obesity and diabetes. Gastrointest Endosc. 2017;86:904-12. DOI PubMed
66. Gagner M, Almutlaq L, Cadiere GB, et al. Side-to-side magnetic duodeno-ileostomy in adults with severe obesity with or without type
2 diabetes: early outcomes with prior or concurrent sleeve gastrectomy. Surg Obes Relat Dis. 2024;20:341-52. DOI PubMed
67. Van Baar ACG, Holleman F, Crenier L, et al. Endoscopic duodenal mucosal resurfacing for the treatment of type 2 diabetes mellitus:
one year results from the first international, open-label, prospective, multicentre study. Gut. 2019;69:295-303. DOI PubMed PMC
68. Haidry RJ, van Baar AC, Galvao Neto MP, et al. Duodenal mucosal resurfacing: proof-of-concept, procedural development, and initial
implementation in the clinical setting. Gastrointest Endosc. 2019;90:673-81.e2. DOI PubMed
69. Mingrone G, Van Baar AC, Devière J, et al. Safety and efficacy of hydrothermal duodenal mucosal resurfacing in patients with type 2
diabetes: the randomised, double-blind, sham-controlled, multicentre REVITA-2 feasibility trial. Gut. 2021;71:254-64. DOI PubMed
PMC
70. Aspire Bariatrics, Inc. AspireAssist instructions for use. 2015. Available from: https://www.accessdata.fda.gov/cdrh_docs/pdf15/
p150024d.pdf. [Last accessed on 20 Jun 2025].
71. Yoon JH, Lee HL. Current status of bariatric endoscopy in obesity control. Korean J Med. 2019;94:5-10. DOI
72. Jirapinyo P, Kumar N, Saumoy M, Copland A, Sullivan S. Association for Bariatric Endoscopy systematic review and meta-analysis
assessing the American Society for Gastrointestinal Endoscopy Preservation and Incorporation of Valuable Endoscopic Innovations
thresholds for aspiration therapy. Gastrointest Endosc. 2021;93:334-42.e1. DOI PubMed
73. Waseem A, Wawrzynski J, Maselli DB, Kucera A, Wooley C, McGowan C. Endoscopic removal of a weight-loss device with stoma
closure using a tack-and-suture device. VideoGIE. 2023;8:441-2. DOI PubMed PMC
74. Köseoğlu HT, Kenarli K, Akbay A, et al. Intragastric injection of botulinum toxin in the treatment of obesity: a single-center study.
Ther Adv Gastrointest Endosc. 2024;17:26317745241233083. DOI PubMed PMC
75. Yen YA, Wang CC, Sung WW, et al. Intragastric injection of botulinum toxin A for weight loss: a systematic review and meta-
analysis of randomized controlled trials. J Gastroenterol Hepatol. 2022;37:983-92. DOI PubMed
76. ASGE/ASMBS Task Force on Endoscopic Bariatric Therapy; Ginsberg GG, Chand B, Cote GA, et al. A pathway to endoscopic
bariatric therapies. Gastrointest Endosc. 2011;74:943-53. DOI PubMed
77. Whaley CM, Briscombe B, Kerber R, O’Neill B, Kofner A. Prices paid to hospitals by private health plans: findings from round 4 of
an employer-led transparency initiative. 2022. Available from: https://www.rand.org/pubs/research_reports/RRA1144-1.html. [Last
accessed on 20 Jun 2025].
78. AMA Category 1 CPT code for endoscopic sleeve gastroplasty (ESG). 2024. Available from: https://www.linkedin.com/posts/boston-
scientific-endoscopy_endobariatrics-cptcode-medicalbillingandcoding-activity-7253049978745487361-9s0b/?utm_source=share&
utm_medium=member_desktop. [Last accessed on 20 Jun 2025].